After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.

The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company ...

Spinnaker Trust raised its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after buying an ...